Replies to post #438 on Oncolytics Biotech Inc. (ONCY)

[secroot]

with all the studies and trials going on, this sure doesn't sound like a one-trick pony----i am looking forward to progress reports

[surf1944]

6:32AM Oncolytics Biotech meets primary overall statistical endpoint in Phase 2 study of REOLYSIN in squamous cell lung cancer (ONCY) 2.99 : Co announces that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy na?ve for their metastatic or recurrent cancer.

The study is a two-stage design with a primary overall endpoint of objective tumor response rate. The co saw a sufficient number of responses in the first stage of the study to proceed with enrollment in the second stage. A total of up to 36 patients were to be studied in the second stage. The primary endpoint was met if nine or more patients in both stages combined had a partial response or better, which yields a true response rate of 35% or more. This endpoint was met after 21 evaluable patients were treated on study, nine of which exhibited PRs, while a further nine showed stable disease and three, progressive disease, for a response rate of 42.8% and a disease control rate of 85.7%.